The partner agreement of Sanofi-aventis and JDRF

1 Звезда2 Звезды3 Звезды4 Звезды5 Звезд (Пока оценок нет)
Загрузка...

Sanofi-aventis and Fund of researches in the field of a diabetes at teenagers (JDRF — Juvenile Diabetes Research Foundation) declared the conclusion of the unique partner agreement on working out of means of treatment for patients with a diabetes of 1 type at various stages of disease – diagnosed earlier or recently, and also for preventive maintenance of a diabetes at persons from risk group. For performance of the planned purposes of the company will concentrate on such directions as immunological preparations and the means directed on regeneration β — cages, it is told in the joint message of Sanofi-aventis and JDRF.Sanofi-aventis and Fund of researches in the field of a diabetes at teenagers (JDRF — Juvenile Diabetes Research Foundation) declared the conclusion of the unique partner agreement on working out of means of treatment for patients with a diabetes of 1 type at various stages of disease – diagnosed earlier or recently, and also for preventive maintenance of a diabetes at persons from risk group. For performance of the planned purposes of the company will concentrate on such directions as immunological preparations and the means directed on regeneration β — cages, it is told in the joint message of Sanofi-aventis and JDRF.

According to the given partner agreement sanofi-aventis and JDRF will in common give to scientific researchers and the noncommercial organizations financing for carrying out of research projects in the field of regeneration and immune therapy. Thanks to the given partnership sanofi-aventis will get access to intellectual property of the researchers receiving financing within the limits of the given program.

«Strategy sanofi-aventis is directed on granting of the therapeutic decisions meeting requirements of patients with a diabetes and their families», – the Senior vice-president of global division of a diabetes sanofi-aventis has declared Pierre Chancel. – «Our insulin of long action – one of leading insulin for patients with a diabetes 1 and 2 types, and we continue to invest in researches for search of additional means of therapy and satisfaction of requirements of patients. The partner agreement with Fund of researches in the field of a diabetes at teenagers (JDRF) gives the chance to us to finance innovative workings out and to improve quality of treatment or maybe even to find means of treatment of a diabetes of 1 type».

Source: sanofi-aventis.com

Добавить комментарий

Your email address will not be published / Required fields are marked *